Clinical Trials in Italy / NCT07785362
Enrolling by invitation Not applicable

Neuro-modulation of Central Pain Pathways in Non Inflammatory Musculoskeletal Pain Syndrome

NCT07785362 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2025-03-31
Last updated
2026-08-25

Condition(s) studied

Pain SyndromeFibromyalgiaCRPS (Complex Regional Pain Syndromes)NeuromodulationJuvenilePhysical DisabilityPhysical Inactivity

Investigational drug(s) / intervention(s)

Neuro-modulation of central pain pathways in non inflammatory musculoskeletal pain syndrome (NMJFP)

Neuro-modulation of central pain pathways in non inflammatory musculoskeletal pain syndrome (NMJFP): Transcranial electrical stimulation (tES) is a non-invasive neuromodulation technique used in this study to investigate its effects on central pain processing in pediatric patients with juvenile fibromyalgia and other non-inflammatory musculoskeletal pain syndromes. The intervention is integrated within a multidisciplinary approach that combines behavioral assessments, neurophysiological measurements, and quality of life evaluations. The study aims to assess the impact of tES on pain reduction, functional improvement, and neurophysiological markers, while ensuring safety and tolerability in a young population. The intervention is delivered using CE-certified equipment and follows international safety guidelines

Study summary

The aim of this clinical trial is to see if transcranial electrical stimulation (tES) can help reduce pain and improve quality of life in children and adolescents (ages 10-21, both sexes) with juvenile fibromyalgia or other non-inflammatory musculoskeletal pain syndromes. The main questions are whether active tES works better than sham (placebo) stimulation for pain relief and whether it leads to measurable changes in brain activity.Participants will be randomly assigned to receive either active or sham tES for 20 minutes a day over two weeks. They'll complete questionnaires about their pain and quality of life, do some simple physical and motor tests, and undergo non-invasive brain measurements before and after the intervention. The results will help understand if tES is a safe and effective option for managing chronic pain in young people.

Specific Aims:

Aim 1a. transcranial stimulation will be associated with significant improvements in pain and functioning (e.g., 30% or greater symptom relief or 20% or greater improvement in QoL) Aim 1b. For each tES condition, estimate mean changes in motor evoked potential (MEP) amplitudes induced by TMS stimulation.

Aim 2. Compare the tES conditions (Active, Sham) in terms of the mean changes in MEP amplitude.

Aim 3. Obtain statistical estimates of variance components needed for the planning of a future study. Therefore, we hypothesize that anodal tES stimulation decreases MEP amplitudes compared to sham tES condition. We further hypothesize that MEP amplitudes are positively correlated. This study will be the first randomized, double-blind, controlled study of tES technology in children as an adjunctive pain management strategy for MPS.

Data from this trial will likely yield information regarding the feasibility and efficacy of tES as a chronic pain-management approach.

Eligibility

Sex
ALL
Min age
10 Years
Max age
21 Years
Healthy volunteers
No
Inclusion Criteria: Subjects aged between 10 and 21 years.Patients with fibromyalgia according to the 1990 criteria of the American College of Rheumatology or Patients with other types of non-inflammatory musculoskeletal pain syndromes.Patients who reported a mean pain score \> 4 on a 10-point visual analog scale (VAS) during the two weeks preceding the clinical trial.Disease duration for more than 6 months, no change in drug treatments during the last month, and lack of response to conventional treatments. Exclusion Criteria: iagnosis of epilepsy or at risk of seizuresPresence of a cardiac pacemakerPresence of an implanted infusion pump, metal plates in the skull, or metal objects in the eye and skull (e.g., after neurosurgical interventions)Past or present history of substance abusePast or present history of neuropsychiatric disorders (major depression and schizophrenia)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ronchetti Anna Bruna Genova GE

More Istituto Giannina Gaslini trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07785362 on ClinicalTrials.gov ↗ ← All trials in Italy